- Home
- RDWR vs OCS Comparison
RDWR vs OCS Comparison
Compare RDWR & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDWR | OCS |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | Israel | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | RDWR | OCS |
|---|---|---|
| Price | $24.23 | $19.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $32.50 | ★ $39.57 |
| AVG Volume (30 Days) | ★ 296.0K | 106.9K |
| Earning Date | 02-11-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $294,636,000.00 | $991,999.00 |
| Revenue This Year | $11.39 | $14.53 |
| Revenue Next Year | $7.43 | $691.13 |
| P/E Ratio | $62.55 | ★ N/A |
| Revenue Growth | ★ 10.40 | N/A |
| 52 Week Low | $18.46 | $14.00 |
| 52 Week High | $31.57 | $23.08 |
Technical Indicators
Market Signals| Indicator | RDWR | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 47.49 |
| Support Level | $23.53 | $19.61 |
| Resistance Level | $24.46 | $21.11 |
| Average True Range (ATR) | 0.57 | 0.74 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 62.20 | 31.45 |
Price Performance
Historical ComparisonAbout RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. It generates the majority of its revenue from the United States.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.